With a $45 million grant from the NIH, UC San Diego researchers and collaborators will launch a nationwide clinical trial to further investigate the therapeutic potential of benfotiamine, a synthetic version of thiamine (B1), as a treatment for Alzheimer’s disease.
While many U.S. policy makers are calling for reshoring and nearshoring to combat trade disruptions caused by COVID-19, new University of California San Diego School of Global Policy and Strategy research suggests retrenchment of global supply chains is unlikely to happen.